Well the answer to the main question is right @WBA
There has been 1 additional patient vetted and treated
If you look at the timeline presented below you will also note the wording changes in a surreptitious way
There are changes but they are very discreet changes in each update. You need to also realise the issues with enrolling patients in the latter part of these trials. It is a pity this was not communicated in a manner which would take the worry out of some posters complaining about delays in timelines. In reality what Jackie has stated in the AGM has or will come to pass
I would like to highlight this paragraph in todays announcement. It basically explains the final delay in reporting completion of phase 2 trials
In the Phase 2 trial of DEP® cabazitaxel, a total of 76 patients were enrolled across sites in the United Kingdom and Australia, with the final patient having now completed treatment. In the latter part of the trial, patient enrolment was focused on certain hard-to-treat cancers, including platinum-resistant ovarian and gastro-oesophageal cancers where encouraging efficacy signals have been observed. Given the challenges faced by patients with these tumours and the advanced nature of their disease,multiple patients who were recruited into the trial subsequently failed clinical, laboratory or radiological screening, which impacted recruitment rates in the latter stage of the trial.
I do not believe we will have to wait much longer for completion of recruitment in monotherapy for both Docetaxel and Irinotecan. The confusing part for me is will it be completion of recruitment and treatment or just competion of recruitment.
What surprised me was the completion of recruitment and treatment for Starpharma's Dep version of Cabazitaxel. If in fact the completion of recruitment was done in January 2023, and dosing regiment was initiated then, and two to three months later treatment was completed, then in fact the timeline for Dep Cabazitaxel was in line with Jackie's comment at the November 22 AGM
Please note Jackie's answer to the question at the Small Cap Conference less than one month ago
FYI
Who can guess my question
29/11/22
DEP® cabazitaxel • Phase 2 trial, ongoing • 75 patients recruited to date, , with final recruitment focused on gastro-oesophageal cancer • Recruitment is expected to complete within 1-2 months
30/01/23
The DEP® cabazitaxel has enrolled 76 patients to date, with the final patients with specific tumour types currently being screened and scheduled for treatment. Recruitment is expected to complete within the next 1-2 months
28/02/23
The DEP® cabazitaxel Phase 2 trial has enrolled 76 patients, with patient recruitment in the final stages and data analysis and biostatistics activities underway
22/03/23
DEP® cabazitaxel • Phase 2 trial, ongoing • 76 patients recruited to date, , with final recruitment focused on gastro-oesophageal cancer • Recruitment in final stages
There was a Q&A session at the ASX Small and Mid-Cap Conference which was not recorded (I recorded it). When Jackie was asked about expectation of completion of the 3 internal DEP Phase 2 trials, she responded with the following
"We are expecting completion of recruitment of those trials within a very short period of time......so cabazitaxel and docetaxel have final patients in screening and on trial......and irinotecan in a similar timeframe.......so I would expect we would be completing recruitment of those within the next month or so"
17/04/23
In the Phase 2 trial of DEP® cabazitaxel, a total of 76 patients were enrolled across sites in the United Kingdom and Australia, with the final patient having now completed treatment
SPL Price at posting:
48.5¢ Sentiment: Buy Disclosure: Held
